Harmonizing Standards and Coding for hESC Research  by Lomax, Geoffrey & McNab, Angela
Cell Stem Cell
CorrespondenceHarmonizing Standards and Coding
for hESC Research
Geoffrey Lomax1 and Angela McNab2,3,*
1California Institute for Regenerative Medicine, 210 King Street, San Francisco, CA 94107, USA
2Department of Health Richmond House, Human Fertilisation and Embryology Authority/Department of Health UK, 79 Whitehall,
London SW1A 2NS, UK
3Present address: 17 Stourhead House, Tachbrook Street, London SW1V 2QE, UK.
*Correspondence: angela.mcnab@dh.gsi.gov.uk
DOI 10.1016/j.stem.2008.02.002The regulation of human embryonic stem
cell (hESC) research has emerged as an
important international policy issue. Many
governments around the world have
sought to advance the field through the
development of regulatory frameworks to
guide research activities (Knowles, 2004),
providing an opportunity to ensure public
confidence and enable a more permissive
policy context. However, proliferation of
these frameworks has raised concerns
among scientists that ‘‘piecemeal’’ regula-
tion may hinder the development of new
therapies.We propose that developing re-
ciprocal policy agreements between juris-
dictions and agreeing on a global coding
information system will maximize the po-
tential benefit for researchers.
Researchers’ concerns regarding the
lack of cohesion across the increasing
number of regulatory frameworks span
a spectrum of policies ranging from ethical
standards for creating and obtaining em-
bryos to licensing, patent, and other intel-
lectual property rules for the use of stem
cell lines and cell-based products. In
contrast, regulations may be viewed as
a means of enhancing public confidence
and enabling a permissive policy context
for the science. Surveys in the UK, such
as the consultation on public attitude to
embryo research, reveal that the existence
of strong regulation gives people confi-
dence in new techniques being permitted.
We recognize the fundamental importance
of maintaining ethical standards for creat-
ing and obtaining embryos for hESC re-
search, and both the Human Fertilisation
and Embryology Authority (HFEA) and the
California Institute for Regenerative Medi-
cine (CIRM) organizational mandates in-
clude the development of regulations for
the safe and ethical procurement of mate-
rial for hESC research. Recently, both orga-
nizations have been involved in delibera-
tions concerning the procurement ofgametes and embryos for research. We
have emerged from these discussions con-
fident that policies can assure the ethical
conduct of research while advancing inter-
national exchange and collaboration to-
ward the development of new therapies.
This sense of optimism is grounded in our
experience from state, regional, national,
and international policy deliberations in-
volving extensive consultation with scien-
tists, policy makers, interest groups, and
the public. In addition, the comparability
of HFEA and CIRM regulations leads us to
believe that most jurisdictional policies,
while not identical, are often, through dis-
cussion and understanding, compatible.
This compatibility arises from the common
approach utilized to address core ethical
concerns. Rather than hinder research,
webelieve this compatibility canbe capital-
ized on to promote exchange and collabo-
ration. Toward this end, we suggest that
efforts be made internationally to develop
clarity through consensus standards for
coding stem cell lines according to policy
criteria. We suggest an international com-
mittee made up of scientists, regulators,
and stem cell banks be convened to ad-
dress this issue.We recognize that jurisdic-
tion policies span a range of governance
levels and that peer-based self regulation
has a vital role. We recommend engaging
this full scope of governance into the forum.
The specific areas that coding should
address will be considered later in this
discussion, but we acknowledge explic-
itly that such coding should allow for the
transparency of difference rather that re-
quiring absolute consensus from the start.
Thereafter, a longer-term agreement on
standards should be an ambition.
International guidelines and regulations
tend to focus on a set of core concerns re-
lated to the creation and use of embryos
for research purposes (Greely, 2006).
Some jurisdictions have permissive poli-Cell Stemcies allowing the creation of embryos for
research purposes. A larger number of ju-
risdictions permit the derivation of stem
cell lines from ‘‘excess’’ or ‘‘surplus’’ em-
bryos originally created for assisted repro-
duction. Others do not allow the derivation
of cell lines but permit the importation and
use of hESC lines (Okie, 2005). Some na-
tions have no regulatory systems specific
to hESC research. Increasingly, jurisdic-
tions are putting such frameworks in
place, conscious of the need to ensure
standards and public confidence.
Fundamental ethical requirements in-
clude review and approval of projects by
an independent panel, and voluntary and
informed consent from participants (Lo-
max et al., 2007). Oversight mechanisms
vary and include bodies at the institu-
tional, regional, national, or international
level or by some coordinated combination
of these elements.
While there is consensus with regard to
the fundamental requirements for review
and consent, policies for material procure-
ment is one area of variation. In particular,
policies regarding payments or reimburse-
ments to oocyte donors are often inconsis-
tent. CIRM has adopted a ‘‘nothing gained,
nothing lost principle’’ in which donors can
receive reimbursement for expenses in-
curred. The UK has an equivalent standard
with regard to reimbursement and alsoper-
mits a policy that allows In vitro fertilization
(IVF) services to be provided at a reduced
cost if oocytes are donated for research.
This ‘‘egg sharing’’ policy takes into ac-
count the costs of stimulation and drugs
used in any cycle of donation. The Interna-
tional Society for Stem Cell Research
(ISSCR) has adopted a flexible policy al-
lowing payments so long as they do not
constitute undue inducement to participate
(Daley et al., 2007). Variation regarding
benefits or reimbursement for gametes
and embryos is important because of theCell 2, March 2008 ª2008 Elsevier Inc. 201
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Source of hESCs Were hESCs derived from embryos created solely for research purposes?




Was derivation of hESC reviewed and overseen by a body independent
of the investigator?
Was voluntary and informed consent obtained?
Reimbursement or
payment polices
Were donors reimbursed for gametes or in excess of direct expenses?
Were donors provided with any other compensation for gametes?
Were donors incentivized to take part in research or donate gametes?implications for the use of the resulting
hESC lines. For example, the CIRM regu-
lations and the U.S. National Academies’
Guidelines adopt an ‘‘acceptably de-
rived’’ standard for hESC lines (National
Research Council, 2005). This standard
requires consent and oversight and sets
limits on payments to donors. One impli-
cation of the ‘‘acceptably derived’’ stan-
dard is that hESC lines from paid gamete
donors are not be available for CIRM-
funded research.
Thus, the core concerns related to the
ethical conduct of hESC research center
around three general issues: (1) source of
hESCs, (2) review and consent proce-
dures, and (3) reimbursement polices.
Within each of these categories there is
variation among jurisdictional policies.
Some commentators may perceive this
variation as a potential impediment to col-
laborative research and will advocate for
consistent standards in which the sharing
of stem cell lines derived from different
standards could not transgress any juris-
diction’s rules.Wewould recommendoth-
erwise. Considering societal differences
over the application of embryo research,
we believe variation is healthy because it
serves to enable the advancement of
promising scientific inquiry in a manner
consistent with the norms and values of
the respective jurisdictions.
We believe an appropriate response is
the development of standards for the doc-
umentation of hESC sources, review, and
consent procedures and remuneration
policies. Perhaps the most logical mecha-
nism is documentation protocols for hESC
banks. Documentation of cell line char-
acteristics is a central function of banks.
The primary aim of the UK Stem Cell
Bank, for example, is to provide access
for researchers to ethically sourced stem
cell lines that havebeensubjected tochar-
acterization and quality control in order to
guarantee their authenticity, purity, and202 Cell Stem Cell 2, March 2008 ª2008 Elsperformance in stem cell research (Healy
et al., 2005). To date, banking protocols
have focused largely on characterizing
the technical and physical qualities of
cell lines. Similar documentation is war-
ranted with regard to ethical criteria.
The challenge in any registry system is to
develop a discrete coding scheme that ad-
dressesvariablesofconcern.For twoof the
core categories described previously,
sources of hESC and payment policies for
gamete donors, we believe the universe of
possibilities is limited, thusmaking discrete
coding feasible. We hesitate to make
specific recommendations, recognizing
any proposed scheme should benefit
from input from a broad constituency.
Rather, we pose key questions relevant to
policy considerations that such a scheme
should answer (Table 1).
In contrast, the review, oversight, and
consent category may prove more chal-
lenging. Evaluating such information for
a hESC cell line is laborious. In a recent
CIRM evaluation involving 21 research in-
stitutions, verification of appropriate con-
sent for imported cell lines was identified
as themajor regulatory challenge. Further,
there are normative differences between
jurisdictions on how reviews are per-
formed. The HFEA requires peer review
of any embryo research and places con-
senting processes as an essential element
within that review. A local ethics commit-
tee scrutinizes consent processes even
before an application for state license is
made. It may be possible to include in
any coding system a question on whether
such independent scrutiny was required
of the project prior to its commencement,
including approval of the ethical sound-
ness of the consent process.
A more fundamental solution to the dif-
ference in standards between jurisdiction
and thepotential inconsistenciesmanaged
by scientists working across borders may
lie in reciprocal policy agreements. For ex-evier Inc.ample, the CIRM regulations explicitly al-
low all stem cell lines derived under HFEA
license or in accordancewith theCanadian
Institutes of Health Research Guidelines to
be used in CIRM-funded research. Recog-
nizing reciprocal standards as a matter of
policy serves to enhance efficiency by
eliminating the need for investigators to
conduct independent reviews. Document-
ing compliance with a jurisdictional stan-
dard for hESC line derivation within a cod-
ing scheme could advance the ethical
conduct of research, improve efficiency,
and promote exchange and collaboration
critical toadvancing the field (Taylor, 2007).
In summary, we believe that most juris-
dictional policies regarding the ethical con-
duct of hESC research are capable of
compatibility. This compatibility can be
capitalized on to advance international ex-
change and collaboration by addressing
a limited set of information needs and by
formally recognizing reciprocal policy ar-
rangements. We recommend the interna-
tional science community join with repre-
sentatives of the regulatory bodies to
establish a forum to first set the principle
issues for coding and agree on a global
coding and information system. Second,
we encourage policy makers to consider
utilizing reciprocal agreements to support
exchanges of hESC lines and cell-based
products. Finally, we suggest that the in-
ternational forum work toward a long-
termobjective of consensus between juris-
dictions on the standards themselves.
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